Research programme: antisense oligonucleotide MDM2 - Idera PharmaceuticalsAlternative Names: GEM 240; HDMAS5; Research programme: anti-MDM2 antisense oligonucleotides
Latest Information Update: 20 Dec 2016
At a glance
- Originator Idera Pharmaceuticals; Johns Hopkins University; University of Alabama
- Developer Genzyme Corporation; Idera Pharmaceuticals; University of Alabama
- Class Antineoplastics; Nucleotides
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer